"I have never seen this much enthusiasm collectively for a class of drugs before," Asthika Goonewardene, a London-based analyst at Bloomberg Industries, tells the reporters. "This is essentially what we call a land grab. There's opportunity, and everybody is going out to find what that opportunity is."